BACKGROUND: Adjuvant chemotherapy of oral uracil/ftorafur (UFT) plus leucovorin (LV) has been accepted as the standard of care in the treatment of patients with stage II and III carcinoma of the colon. The objective of the study was to compare HRQOL reported by patients receiving oral UFT plus LV (UFT/LV group) versus no adjuvant treatment (control group) following surgery for colorectal cancer. METHODS: Ninety nine patients in the UFT/LV group and 83 in the control group participated. HRQOL was assessed with the European Organization for Research and Treatment of Cancer QLQ-C30 and HRQOL data measured longitudinally following surgery were compared between the groups. RESULTS: Eighty-eight percent (87 of 99) received all scheduled doses of UFT plus LV during the first three cycles, and 82 percent (81 of 99) did so for five cycles. The most common type of toxicity in the UFT/LV group was fatigue, which was generally mild. Six patients each had grade 3 diarrhea or anorexia. There were significant differences in the scores for role function, and specific limitations such as fatigue, nausea, and vomiting, dyspnoea, appetite loss, and financial difficulties, which deteriorated in the UFT/LV group. CONCLUSIONS: HRQOL in colorectal cancer patients with adjuvant chemotherapy with oral UFT plus LV deteriorated during this phase of treatment compared with those with surgery alone, despite the biased stage of tumor between the groups. Symptom management and social support would improve HRQOL in such a group of patients.
BACKGROUND: Adjuvant chemotherapy of oral uracil/ftorafur (UFT) plus leucovorin (LV) has been accepted as the standard of care in the treatment of patients with stage II and III carcinoma of the colon. The objective of the study was to compare HRQOL reported by patients receiving oral UFT plus LV (UFT/LV group) versus no adjuvant treatment (control group) following surgery for colorectal cancer. METHODS: Ninety nine patients in the UFT/LV group and 83 in the control group participated. HRQOL was assessed with the European Organization for Research and Treatment of Cancer QLQ-C30 and HRQOL data measured longitudinally following surgery were compared between the groups. RESULTS: Eighty-eight percent (87 of 99) received all scheduled doses of UFT plus LV during the first three cycles, and 82 percent (81 of 99) did so for five cycles. The most common type of toxicity in the UFT/LV group was fatigue, which was generally mild. Six patients each had grade 3 diarrhea or anorexia. There were significant differences in the scores for role function, and specific limitations such as fatigue, nausea, and vomiting, dyspnoea, appetite loss, and financial difficulties, which deteriorated in the UFT/LV group. CONCLUSIONS: HRQOL in colorectal cancerpatients with adjuvant chemotherapy with oral UFT plus LV deteriorated during this phase of treatment compared with those with surgery alone, despite the biased stage of tumor between the groups. Symptom management and social support would improve HRQOL in such a group of patients.
Authors: K Kobayashi; F Takeda; S Teramukai; I Gotoh; H Sakai; S Yoneda; Y Noguchi; H Ogasawara; K Yoshida Journal: Eur J Cancer Date: 1998-05 Impact factor: 9.162
Authors: Barry C Lembersky; H Samuel Wieand; Nicholas J Petrelli; Michael J O'Connell; Linda H Colangelo; Roy E Smith; Thomas E Seay; Jeffrey K Giguere; M Ernest Marshall; Andrew D Jacobs; Lauren K Colman; Atilla Soran; Greg Yothers; Norman Wolmark Journal: J Clin Oncol Date: 2006-05-01 Impact factor: 44.544
Authors: Jacek A Kopec; Greg Yothers; Patricia A Ganz; Stephanie R Land; Reena S Cecchini; H Samuel Wieand; Barry C Lembersky; Norman Wolmark Journal: J Clin Oncol Date: 2007-02-01 Impact factor: 44.544
Authors: Jean-Yves Douillard; Paulo M Hoff; Jamey R Skillings; Peter Eisenberg; Neville Davidson; Peter Harper; Mark D Vincent; Barry C Lembersky; Seth Thompson; Antonella Maniero; Steven E Benner Journal: J Clin Oncol Date: 2002-09-01 Impact factor: 44.544
Authors: A Tsunoda; N Yasuda; K Nakao; N Yokoyama; T Marumori; H Hashimoto; M Kusano; K West Journal: Qual Life Res Date: 2007-12-20 Impact factor: 4.147
Authors: N K Aaronson; S Ahmedzai; B Bergman; M Bullinger; A Cull; N J Duez; A Filiberti; H Flechtner; S B Fleishman; J C de Haes Journal: J Natl Cancer Inst Date: 1993-03-03 Impact factor: 13.506
Authors: A Zaniboni; R Labianca; S Marsoni; V Torri; P Mosconi; R Grilli; G Apolone; S Cifani; A Tinazzi Journal: Cancer Date: 1998-06-01 Impact factor: 6.860
Authors: Christine L Paul; Emilie Cameron; Christopher Doran; David Hill; Finlay Macrae; Mariko L Carey; Rob W Sanson-Fisher Journal: Support Care Cancer Date: 2016-07-16 Impact factor: 3.603
Authors: A G K McNair; R N Whistance; R O Forsythe; J Rees; J E Jones; A M Pullyblank; K N L Avery; S T Brookes; M G Thomas; P A Sylvester; A Russell; A Oliver; D Morton; R Kennedy; D G Jayne; R Huxtable; R Hackett; S J Dutton; M G Coleman; M Card; J Brown; J M Blazeby Journal: Colorectal Dis Date: 2015-11 Impact factor: 3.788